Periscope thinks pink with new lighted folio
RIDGEWOOD, N.J. A maker of deluxe e-reader covers has released a new version of its lighted folio.
Periscope released its new pink lighted folio in line with National Breast Cancer Awareness Month, the company said. Available for a suggested retail price of $49.95, the Periscope lighted folio is an “all-in-one” item that features a retractable Periscope twin LED reading light, deluxe cover and notebook/pen holder in one fashionably designed pink leatherette unit.
“With today’s debut of the pink lighted folio for both the [Amazon] Kindle 2 and [Barnes & Noble] Nook e-readers, and with National Breast Cancer Awareness Month occurring in October, we decided there was no better time to show our support of those whose lives have been affected by breast cancer,” Periscope president Eric Fisherman said. “The new pink lighted folio makes an ideal gift choice for gift-givers who wish to give a gift that has a greater significance. Now every time a consumer uses their pink lighted folio, they will be reminded of all those whose lives have been touched in any way by breast cancer.
Watson confirms patent challenge for generic Combigan
MORRISTOWN, N.J. Generic drug maker Watson Pharmaceuticals has applied for Food and Drug Administration approval for a version of a drug used to treat eye diseases, Watson said Tuesday.
Watson announced that subsidiary Watson Labs had filed for approval of brimonidine tartrate and timolol maleate ophthalmic solution in the 0.2%/0.5% strength. The drug is a generic version of Allergan’s Combigan, used to reduce pressure inside the eye, also known as intraocular pressure, in patients with glaucoma or ocular hypertension for whom current or previous therapies are ineffective.
The drug had sales of around $98 million during the 12-month period ended in July, according to IMS Health.
Allergan filed a patent infringement suit against Watson earlier this month in the U.S. District Court for the Eastern District of Texas in order to prevent Watson from marketing its version of the drug before the expiration of four patents covering Combigan, the last of which expires in January 2023, according to FDA records; the exclusivity period for the drug expires at the end of October of this year. Under the Hatch-Waxman Act, Allergan’s lawsuit places a stay on final FDA approval of Watson’s drug for 2.5 years, or until the two companies resolve the matter before the court.
Study: Patients increasingly turn to ER for acute ailments
NEW YORK Millions of patients with such acute ailments as fevers and coughs turn to the emergency room for treatment, according to researchers. The findings serve as yet one more indicator for the need of convenient and affordable health services available at retail-based clinics.
Today, only 42% of the 354 million annual visits for acute care are made to patients’ primary physicians. The rest are made to emergency departments (28%), specialists (20%) or outpatient departments (7%), according to the study titled "Where Americans Get Acute Care: Increasingly, It’s Not At Their Doctor’s Office."
The study, which examined records of acute care visits from 2001 to 2004, was published Tuesday in the journal Health Affairs.
Although fewer than 5% of doctors are emergency physicians, they handle a quarter of all acute care encounters and more than half of such visits by the uninsured, according to the study.
The study, which also was highlighted in The New York Times, calls into question how U.S. health care can be improved when an already overloaded system takes on some 30 million newly insured customers, thanks to healthcare reform.